NEW YORK (GenomeWeb News) – Exact Sciences said after the close of the market Tuesday that the US Food and Drug Administration's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the firm's premarket approval application for its Cologuard DNA-based, non-invasive colorectal cancer screening test on March 26, 2014.

The date is subject to confirmation by the FDA in the Federal Register.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.